JANX.US Janux Therapeutics Inc

Healthcare Biotechnology USA Stocks
11.37 USD
Close of Nov 15, 2026
11.16 35.34
Market cap
USD 696M
P/E
-
P/B
0.76x
ROE
-9.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is JANX.US undervalued?

Graham number

The Graham number of Janux Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Janux Therapeutics Inc fundamental analysis

No fundamental analysis for Janux Therapeutics Inc yet.

Janux Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Janux Therapeutics Inc

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-res…

Full company profile